Vildagliptin and the Glucagon Response to Hypoglycemia in Insulin-Treated Patients With Type 2 Diabetes

• Status: Completed
• Trial end date: 2013-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to explore whether the novel therapy of type 2 diabetes, vildagliptin, which inhibits dipeptidyl peptidase-4 (DPP-4), affects glucagon counterregulation during hypoglycemia in insulin-treated patients with type 2 diabetes. Vildagliptin is given, together with the on-going insulin therapy, for one month, whereafter hypoglycemia is induced under standardized conditions, and the glucagon response is determined, and compared to that after a month of placebo treatment.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Lund University
• Treatments: Glucagon; Glucagon-Like Peptide 1; Insulin; Vildagliptin

Criteria

Inclusion Criteria:

• Type 2 diabetes

• Insulin treatment

• Age >18 years

• HbA1c <=8.5%

Exclusion Criteria:

• Pregnancy

• Lactation

• Acute infection

• Liver disease

• Treatment with cortisol